Cognate BioServices, Inc.

24 articles about Cognate BioServices, Inc.

• Charles River Laboratories Completes the Acquisition of Cognate BioServices

  3/29/2021

  Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary closing adjustments.

• Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development

  2/17/2021

  Acquiring Cognate Bioservices - – Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector – – Combines Cognate’s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery through CGMP Manufacturing – WILMINGTON, Mass.--( BUSINESS WIRE )-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate Bio

• 

  Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

  2/17/2021

  Charles River Laboratories will acquire Cognate BioServices in an $875 million cash deal that will significantly expand the company’s capabilities in the high-growth cell and gene therapy sector.
• 

  Life Sciences Job Expansions Continue to Soar Throughout Pandemic

  2/9/2021

  Here’s a recap of companies announcing facility expansions this past month and life sciences job creations across the nation.

• Cognate BioServices Announces Major Expansion of Manufacturing Facilities in US and Europe

  1/14/2021

   Cognate BioServices, Inc., the premier commercial-ready, global CDMO in the Cell and Gene Therapy industry, announced today its plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and increase office support at its facilities in the United States and Europe .

• Cognate BioServices, the Leading Biologics CDMO, Selects L7 Informatics to Implement L7|ESP for Integrated Manufacturing and Lab Operations

  12/10/2020

   L7 Informatics announced that it has partnered with Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, to deploy L7|ESP (Enterprise Science Platform) and implement an integrated manufacturing and lab system. Specifically, L7 will provide Cognate BioServices with a unified data and

• Cognate BioServices Names Tom Pamukcoglu as VP, Global Head of Quality

  11/2/2020

  Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, announced the appointment of Tom Pamukcoglu as Vice President – Global Head of Quality.

• Cognate BioServices Announces the Appointment of Two Independent Board Members

  8/20/2020

  Cognate BioServices, Inc. announced today the appointments of Timothy Moore and Steven Kasok as independent non-executive members of its Board of Directors. "We are excited to welcome Tim Moore and

• Cognate BioServices Reveals New Brand Identity with Redesigned Logo and Website

  8/6/2020

  Cognate BioServices, Inc., the premier contract development and manufacturing organization specializing in cell and cell-mediated gene therapy products, announced the launch of its new corporate brand identity, redesigned logo, and website across its portfolio of services and companies.

• Cobra Biologics delivers final plasmids for production of CG01 in CombiGene's epilepsy project

  7/13/2020

  Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy

• Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

  1/21/2020

  Cognate BioServices, a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapy products announced that it has completed the acquisition of Cobra Biologics, a leading CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector.

• Cognate BioServices announces acquisition of Cobra Biologics

  11/4/2019

  Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products

• Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry

  8/26/2019

  Cognate BioServices announced it has secured a financial sponsor to support its short-term and long-term growth as it closed on a round of growth capital from EW Healthcare Partners.

• Cognate BioServices, Inc. (Memphis, TN) receives Statement of Compliance to EU Good Manufacturing Practice for manufacture of Advanced Therapeutic Medicinal Products

  6/10/2019

  Cognate BioServices, Inc., a leading contract development and manufacturing organization in the global cellular therapies industry, announced that It has received a statement of compliance for the manufacture and development of advanced therapy medicinal products for EU/UK.

• Cognate BioServices and Astero Bio Corporation Announce Collaboration for Innovation and Development Center of Excellence in Memphis, TN

  1/23/2019

  Cognate BioServices, Inc. today announced a letter of intent for a collaboration with Astero Bio Corporation, a leader in the development of innovative tools for cryopreserved biologics, to increase the accessibility of automated cell thawing technologies. 

• Cognate BioServices and Terumo BCT Announce Letter of Intent for Collaboration Agreement for Innovation and Development Center of Excellence in Memphis, TN.

  10/3/2018

  Cognate BioServices today announced a letter of intent for a collaboration agreement with Terumo BCT, a leading technology provider in the cell therapy market.

• Cognate BioServices and FloDesign Sonics Announce Collaboration to Advance Acoustic Cell Processing as a Platform for Cell Therapy Manufacturing

  9/4/2018

  FloDesign Sonics and Cognate BioServices today announced a technology development collaboration agreement to advance the accessibility of life saving therapeutics.

• Cognate Completes Management Buyout and Raises Growth Capital

  2/20/2018

  Cognate BioServices announced today it has completed a management buyout (“MBO”) and raised capital from a group of global investment firms.

• Cognate BioServices, Inc. Announces Strategic Collaboration With Terumo BCT

  10/3/2016

• NASDAQ Accepts NW Bio Remediation Plan For Shares And Warrants Previously Issued To Cognate BioServices, Inc.

  9/6/2016